Last updated: February 25, 2026
What is NDC 71930-0028?
NDC 71930-0028 designates a specific pharmaceutical product listed in the United States National Drug Code database. It corresponds to Vyvgart (efgartigimod alfa-fcab), a monoclonal antibody approved for the treatment of generalized Myasthenia Gravis (gMG) in adult patients who are anti-AChR antibody positive. The drug was approved by the FDA in December 2022.
Market Overview
Indications and Patient Population
Vyvgart targets a rare autoimmune disorder—Myasthenia Gravis—a neuromuscular disease characterized by weakness in skeletal muscles. Estimated US prevalence is approximately 15,000-20,000 patients, with the subset of anti-AChR antibody-positive cases approaching 60-70% of oral immunotherapy candidates.
Competitive Landscape
- Main competitors:
- Soliris (eculizumab); approved for generalized MG since 2017
- Ultomiris (ravulizumab); approved for MG in certain settings
- Efgartigimod (Vyvgart); offers a novel mechanism via neonatal Fc receptor inhibition
Market Dynamics
- Unmet Need: Limited therapeutic options with tissue-specific mechanisms
- Pricing:
- Vyvgart's list price approaches $6,000 per dose
- Dosing regimen: 10 mg/kg weekly for 4 weeks, then every 2 weeks
Regulatory Status and Launch Timing
- US approval: December 2022
- Launch: Q1 2023
- Market penetration anticipates growth driven by clinician familiarity and prior success with immunoglobulin treatments
Price Projections
Initial Price Point
- Launch list price: ~$6,000 per dose
- Average annual cost: approximately $180,000 to $240,000 per patient (assuming 12 doses annually)
Market Penetration and Sales Forecast
| Year |
Estimated Patients |
Estimated Penetration |
Projected Revenue (USD) |
| 2023 |
2,000 |
10% |
$360 million |
| 2024 |
4,000 |
20% |
$720 million |
| 2025 |
6,000 |
30% |
$1.1 billion |
| 2026 |
8,000 |
40% |
$1.4 billion |
| 2027 |
10,000 |
50% |
$1.8 billion |
Assumptions:
- Growth in patient numbers due to increased diagnostic awareness
- Steady adoption by neurologists and neuromuscular specialists
- No significant price reductions or discounts
Price Sensitivity Factors
- Reimbursement policies: Commercial and Medicare coverage impact patient access
- Competitive pricing: Soliris and Ultomiris have higher per-dose costs but longer market presence
- Manufacturing costs: Biologic production affects gross margins; expected to decline over time
Pricing Strategy Risks
- Adoption delays from payer negotiations
- Rebate programs reducing net price
- Potential biosimilar entrants after patent expiry (expected post-2030)
Patent and Market Exclusivity
- Patent protection lasts until at least 2032
- Exclusivity extensions may occur based on biologic licensing pathway
Key Market Drivers
- Increasing MG diagnosis rates
- Off-label expansion for other autoimmune indications
- Physician and patient preference for targeted therapies over plasma exchange or IVIG
Potential Market Disruptors
- Entry of biosimilar competitors post-patent expiry
- Development of alternative immunomodulatory treatments
- New combination therapies that improve efficacy
Pricing Comparisons with Similar Biologics
| Product |
List Price per Dose |
Indication |
Market Entry Year |
| Soliris |
~$6,000 |
MG, paroxysmal nocturnal hemoglobinuria |
2017 |
| Ultomiris |
~$6,600 |
MG, PNH |
2020 |
| Vyvgart |
~$6,000 |
MG |
2022 |
Note: Vyvgart's initial pricing aligns with existing complement inhibitors, justified by mechanism and clinical impact.
Regulatory and Market Risks
- Potential delays if safety concerns arise
- Market growth hampered if physicians prefer long-established therapies
- Insurance coverage hurdles could limit patient access
Summary
Vyvgart (NDC 71930-0028) enters a niche market with a targeted, rapidly growing patient base in MG. Initial list prices around $6,000 per dose position the drug as a premium biologic, with projected annual revenue reaching approximately $1.8 billion by 2027 if market penetration grows as anticipated. Long-term price trajectory will depend on payer dynamics, competitive responses, and patent protections.
Key Takeaways
- Vyvgart’s geographic launch began in Q1 2023, with steady adoption expected.
- Pricing remains stable initially; significant revenue accrues as patient numbers increase.
- Competition from existing biologics influences market dynamics more than new entrants initially.
- Reimbursement policies and physician uptake determine actual market penetration.
- Biosimilar entry after patent expiry could influence long-term price erosion.
FAQs
-
What is the expected pricing trend beyond the initial years?
Prices are likely to stabilize as payer negotiations solidify. Long-term discounts may occur post-patent expiry.
-
How does Vyvgart's price compare to existing MG treatments?
It is comparable to Soliris and Ultomiris, both costing around $6,000 per dose, with annual costs near $200,000.
-
What factors could accelerate market growth?
Increased diagnosis, expanded clinician familiarity, and positive real-world evidence support growth.
-
When might biosimilar competitors emerge?
Post-2030, following patent expiration and biosimilar development timelines.
-
How does payer coverage influence price projections?
Coverage decisions, reimbursement levels, and formulary placements directly impact net pricing and patient access.
References
-
U.S. Food and Drug Administration. (2022). Vyvgart (efgartigimod alfa-fcab) approval letter. Retrieved from [FDA website].
-
IQVIA. (2023). Market Trends in Myasthenia Gravis Treatments. [Internal report].
-
Pharma Intell. (2023). Biologic Pricing and Market Dynamics. [Industry report].
-
Targeted Oncology. (2023). Myasthenia Gravis: New Treatments and Market Outlook. [Article].
-
Patentscope. (2023). Vyvgart Patent Summary. [Patent database].
[1] U.S. Food and Drug Administration. (2022). Vyvgart (efgartigimod alfa-fcab) approval letter. https://www.fda.gov/
